Heart Failure Market To Reach $53 Billion By 2032, Predicts GlobalData

According to media reports, Global Data has forecasted a compound annual growth rate (CAGR) of 5.2 per cent from USD 31.9 billion in 2022 to USD billion in 2032 for the heart failure market. This forecast is based on seeing the huge influx of patients and these trends are anticipated to extend across the seven key markets, namely the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan, the reports in media stated.

Kajal Jaddoo, Senior Pharma Analyst, at GlobalData, while speaking with the media said, “The pressure for pharmaceutical companies to be more innovative with their therapies and tackle unmet needs is increasing. Companies are approaching the HF market with the strategies of optimising treatment safety and compliance, as well as developing novel drug classes. The use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers has remained relatively consistent, and the use of sodium-glucose transporter 2 inhibitors has become well established for HF.”

Reports in media suggest that during the forecasted timeframe spanning from 2022 to 2032, GlobalData foresees the introduction of several promising pipeline medications, including Tirzepatide, omecamtiv mecarbil, Neucardin, and Kerendia. 

On the whole, cardiologists surveyed by GlobalData have conveyed a moderately positive outlook on the HF pipeline.